Uterine Fibroids - Drug Pipeline Landscape, 2023
Description
Uterine Fibroids - Drug Pipeline Landscape, 2023
Uterine fibroids are a common type of noncancerous tumor that can grow in and on your uterus. Uterine fibroids are found incidentally during a routine pelvic exam.
The causes of fibroids are unknown. Most fibroids happen in people of reproductive age. Possible causes include genetic changes, hormones, other growth factors and extracellular matrix.
Uterine fibroids patients may have symptoms, including excessive or painful menstruation, bloating, frequent urination, pain during intercourse, low back pain, constipation, chronic vaginal discharge and increased abdominal distention.
Uterine fibroids patients with symptoms may have to take the tests like ultrasound, lab tests and other imaging tests including MRI, hysterosonography, hysterosalpingography and hysteroscopy.
Treatment options for uterine fibroids can include over-the-counter (OTC) pain medications, gonadotropin-releasing hormone (GnRH) agonists, iron supplements, oral therapies and birth controls.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Uterine Fibroids treatment such as Linzagolix, TU-2670, and others. Key players involved in the development of therapies to treat Uterine Fibroids are Kissei Pharmaceutical Co Ltd, TiumBio Co Ltd, and others. One drug is under Phase III clinical trials and one drug are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Nov 2022, Tium Bio transferred the technology rights to China’s Hanso Pharmaceutical for China development of TU2670.
Report Highlights
Global Insight Service's, Uterine Fibroids - Drug Pipeline Landscape, 2023 report provides an overview of the Uterine fibroids pipeline drugs. This report covers detailed insights on Uterine Fibroids drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Uterine Fibroids pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Uterine fibroids are a common type of noncancerous tumor that can grow in and on your uterus. Uterine fibroids are found incidentally during a routine pelvic exam.
The causes of fibroids are unknown. Most fibroids happen in people of reproductive age. Possible causes include genetic changes, hormones, other growth factors and extracellular matrix.
Uterine fibroids patients may have symptoms, including excessive or painful menstruation, bloating, frequent urination, pain during intercourse, low back pain, constipation, chronic vaginal discharge and increased abdominal distention.
Uterine fibroids patients with symptoms may have to take the tests like ultrasound, lab tests and other imaging tests including MRI, hysterosonography, hysterosalpingography and hysteroscopy.
Treatment options for uterine fibroids can include over-the-counter (OTC) pain medications, gonadotropin-releasing hormone (GnRH) agonists, iron supplements, oral therapies and birth controls.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Uterine Fibroids treatment such as Linzagolix, TU-2670, and others. Key players involved in the development of therapies to treat Uterine Fibroids are Kissei Pharmaceutical Co Ltd, TiumBio Co Ltd, and others. One drug is under Phase III clinical trials and one drug are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Nov 2022, Tium Bio transferred the technology rights to China’s Hanso Pharmaceutical for China development of TU2670.
Report Highlights
Global Insight Service's, Uterine Fibroids - Drug Pipeline Landscape, 2023 report provides an overview of the Uterine fibroids pipeline drugs. This report covers detailed insights on Uterine Fibroids drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Uterine Fibroids pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
67 Pages
- 1. Introduction
- 1.1 Uterine Fibroids - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Uterine Fibroids
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Uterine Fibroids - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs – Phase III
- 5.1.1 Linzagolix
- 5.2 Clinical Stage Drugs – Phase II
- 5.2.1 TU-2670
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 EN3835
- 5.3.2 SHR7280
- 5.4 Early-Stage Drugs – Preclinical
- 5.4.1 EC313
- 5.5 Early-Stage Drugs – Discovery
- 5.5.1 EVE132
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Endo Pharma
- 9.2 Evestra Inc
- 9.3 Jiangsu HengRui Medicine Co Ltd
- 9.4 Kissei Pharmaceutical Co Ltd
- 9.5 TiumBio Co Ltd
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - Linzagolix/Kissei Pharmaceutical Co., Ltd.
- Table 2. 2 Clinical Trial Details - EN3835/Endo Pharm
- Table 2. 3 Clinical Trial Details - SHR7280/Jiangsu HengRui Medicine Co., Ltd.
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Uterine Fibroids, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Uterine Fibroids, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Uterine Fibroids, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Uterine Fibroids, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Uterine Fibroids, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
